New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
10:11 EDTDVAX, DEPO, SM, GLF, ASNA, TEVA, CBSH, PLCE, PETM, NVE, ENDP, ARO, WPZ, OC, TGP, BP, TDW, NBL, BRY, ABAX, HNZ, ALUOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abaxis (ABAX) downgraded to Underperform from Neutral at BofA/Merrill... Aeropostale (ARO) downgraded to Hold from Buy at KeyBanc... Affymax (AFFY) downgraded to Neutral from Outperform at RW Baird... Ascena Retail (ASNA) downgraded to Hold from Buy at KeyBanc... Berry Petroleum (BRY) downgraded to Neutral from Positive at Susquehanna... Endo Health (ENDP) downgraded to Underweight from Neutral at Piper Jaffray... GulfMark Offshore (GLF) downgraded to Buy from Strong Buy at ISI Group... NV Energy (NVE) downgraded to Hold from Buy at Wunderlich... Noble Energy (NBL) downgraded to Buy from Conviction Buy at Goldman... SM Energy (SM) downgraded to Market Perform from Outperform at BMO Capital... Tidewater (TDW) downgraded to Neutral from Buy at ISI Group... PetSmart (PETM) downgraded to Equal Weight from Overweight at Johnson Rice... Depomed (DEPO) downgraded to Hold from Buy at WallachBeth... BP (BP) downgraded to Buy from Strong Buy at ISI Group... Children's Place (PLCE) downgraded at Janney Capital... Dynavax (DVAX) downgraded to Hold from Buy at MLV Equity... Teekay LNG (TGP) downgraded at Raymond James... Commerce Bancshares (CBSH) downgraded at Raymond James... Alcatel-Lucent (ALU) downgraded to Underweight from Neutral at HSBC... Teva (TEVA) downgraded to Hold from Buy at Argus... Owens Corning (OC) downgraded to Market Perform from Outperform at Wells Fargo... Heinz (HNZ) downgraded to Neutral from Buy at Citigroup... Williams Partners (WPZ) downgraded to Accumulate from Buy at Global Hunter.
News For ABAX;ARO;ASNA;BRY;ENDP;GLF;NBL;NVE;SM;TDW;PETM;DEPO;BP;PLCE;DVAX;TGP;CBSH;ALU;OC;TEVA;HNZ;WPZ From The Last 14 Days
Check below for free stories on ABAX;ARO;ASNA;BRY;ENDP;GLF;NBL;NVE;SM;TDW;PETM;DEPO;BP;PLCE;DVAX;TGP;CBSH;ALU;OC;TEVA;HNZ;WPZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 14, 2014
05:54 EDTBPBP upgraded to Buy from Hold at Canaccord
Subscribe for More Information
April 11, 2014
09:05 EDTPLCEChildren's Place turnaround opportunities compelling, says FBR Capital
FBR Capital believes Children's Place offers one of the most compelling turnaround opportunities in specialty retail. FBR says it is more positive on the company's turnaround story after meeting with management and it reiterates an Outperform rating on the name with a $60 price target.
09:04 EDTAROAeropostale price target lowered to $5 from $7.50 at BofA/Merrill
Subscribe for More Information
08:11 EDTBPBP says can help improve relations between west, Russia, Reuters says
In an effort to calm shareholders' worries over the company's large exposure to Russia, BP executives said it can help improve relations between Russia and the west and is talking to politicians all over the globe, according to Reuters, citing comments from CEO Bob Dudley. Reference Link
April 10, 2014
07:06 EDTCBSHCommerce Bancshares reports Q1 EPS 67c, consensus 68c
Subscribe for More Information
April 9, 2014
15:19 EDTCBSHNotable companies reporting before tomorrow's open
Subscribe for More Information
10:06 EDTAROOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
April 8, 2014
17:04 EDTAROAeropostale downgraded to Underweight from Neutral at Piper Jaffray
Subscribe for More Information
14:11 EDTNBLWoodside expected to reach deal with Israel on Leviathan tax, Globes says
Subscribe for More Information
08:46 EDTTEVATeva announces first approval, launch of generic Lovaza capsules in the U.S.
Teva (TEVA) announces the approval of the generic equivalent to Lovaza in the United States. Teva believes it is first-to-file and thus far is the only company to receive an approval from FDA. Teva plans to commence shipping immediately. Lovaza Capsules, marketed by GlaxoSmithKline (GSK), had annual sales of approximately $1.1B in the United States, according to IMS data as of December 2013.
08:02 EDTABAXAbaxis receives Health Canada Class III approval for Piccolo Xpress
Abaxis announced Health Canada approved the Piccolo Xpress and Piccolo Reagent Discs as a Class III medical device for use throughout Canada. With this reclassification, Canadian healthcare providers and patients can now enjoy the benefits of lab-accurate blood chemistry diagnostics at the point-of-care.
April 7, 2014
16:21 EDTWPZGastar Exploration says Marcellus Shale production temporarily interrupted
Subscribe for More Information
14:09 EDTTEVASun Pharmaceutical agrees to acquire generic drugmaker Ranbaxy
Subscribe for More Information
April 4, 2014
10:45 EDTTEVAMylan rises despite Meda rejecting takeover offer
Mylan (MYL) shares are higher this morning following a Financial Times report of its desire to buy Swedish rival Meda. Subsequent to the story being published, Meda confirmed it had been in talks with Mylan but rejected the company's takeover offer. WHAT'S NEW: The Financial Times reported that Mylan was considering buying Meda, a Swedish drugmaker, in a deal that would create a $23B+ pharmaceuticals business. Mylan reportedly hired advisers to put a deal together for Meda, and though the value of a deal was not noted, sources said Mylan was likely to pay a "significant" premium to Meda's market value, which was $4.5B at the end of trading on Thursday. Mylan's market value currently stands at $18.5B. A combination of the drugmakers would create a company with annual revenues of around $9B, the FT said, noting that would be half the size of generic drug rival Teva (TEVA). WHAT'S NOTABLE: Meda's board of directors confirmed that it was contacted by Mylan regarding a proposal to merge the companies, but the board decided to reject the proposal. Meda said all discussions between the company and Mylan have been terminated "without further actions." ANALYST REACTION: Citigroup upgraded Mylan to Buy from Neutral and raised its price target on the stock to $61 from $52 this morning. The firm cited potential operational and tax benefits from an acquisition of Meda, stating that in addition to expanding Mylan's geographic presence, the deal would increase its presence in specialty, OTC and branded generics. OTHER NEWS: Mylan sued Celgene (CELG) to block that company's efforts to keep generic versions of Revlimid and Thalomid off the market, Reuters reported. PRICE ACTION: Mylan shares are up $2.98, or 5.98%, to $52.84 in mid-morning trading.
07:25 EDTNBLAnadarko price target raised to $120-$130 from $110-$120 at Wells Fargo
Wells Fargo increased its price target on Anadarko after the company announced that it had settled the Tronox case for a lower than expected amount. The firm thinks the stock's discount to its peers EOG Resources (EOG) and Noble Energy (NBL) is unjustified. Wells keeps an Outperform rating on Anadarko.
April 3, 2014
17:51 EDTAROAeropostale files form to delay 10-K
Subscribe for More Information
14:30 EDTTEVAMylan says USPTO rejects Teva '808 patent reissue application on Copaxone
Subscribe for More Information
14:28 EDTTEVAMylan says USPTO rejects Teva '808 patent reissue application on Copaxone
Subscribe for More Information
10:00 EDTBPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:43 EDTBPBP initiated with a Market Perform at BMO Capital
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use